Stuart JC, et al. - In this retrospective observational case-series of patients with a urinary tract infection (UTI) caused by an extended-spectrum β-lactamase (ESBL)-producing micro-organism, researchers investigated the clinical and bacteriological effect of oral treatment with ceftibuten plus amoxicillin-clavulanic acid. Ten patients with pyelonephritis caused by an ESBL-positive micro-organism resistant to ciprofloxacin and co-trimoxazole received oral treatment with ceftibuten 400 mg QD plus amoxicillin-clavulanic acid 625 mg TID for 14 days and experienced clinical cure. All eight patients with follow-up cultures showed bacteriological cure (absence of pretreatment micro-organism in the first follow-up culture obtained within 3 months after treatment). Findings thus suggest the efficacy of the synergistic combination of ceftibuten plus amoxicillin-clavulanic acid for oral treatment of UTIs caused by ESBL producing E. coli or K. pneumoniae.